* patients with severe form of covid-19 infection defined as the presence of crackles observed during clinical exam, associated with less than 94% oxygen saturation or patients with respiratory insufficiency on oxygen therapy or mechanical ventilation * previous treatment with hydroxychloroquine or azithromycine for covid-19 infection * qtc interval greater than 480 ms * hypersensibility to hydroxychloroquine or azithromycine * retinopathy * tgo or tgp geater than 5 x the normal upper limit * creatinine clearance lower than 30 ml/min * concomitant treatment that may lead to prolongation of the qt space * concomitant treatment with dihydroergotamine, ergotamine, cisapride or colchicine * known g6pd deficiency

* patients with severe form of covid-19 infection defined as the presence of crackles observed during clinical exam, associated with less than 94% oxygen saturation or patients with respiratory insufficiency on oxygen therapy or mechanical ventilation * previous treatment with hydroxychloroquine or azithromycine for covid-19 infection * qtc interval greater than 480 ms * hypersensibility to hydroxychloroquine or azithromycine * retinopathy * tgo or tgp geater than 5 x the normal upper limit * creatinine clearance lower than 30 ml/min * concomitant treatment that may lead to prolongation of the qt space * concomitant treatment with dihydroergotamine, ergotamine, cisapride or colchicine * known g6pd deficiency

- patients with severe form of covid-19 infection defined as the presence of crackles observed during clinical exam, associated with less than 94% oxygen saturation or patients with respiratory insufficiency on oxygen therapy or mechanical ventilation - previous treatment with hydroxychloroquine or azithromycine for covid-19 infection - qtc interval greater than 480 ms - hypersensibility to hydroxychloroquine or azithromycine - retinopathy - tgo or tgp geater than 5 x the normal upper limit - creatinine clearance lower than 30 ml/min - concomitant treatment that may lead to prolongation of the qt space - concomitant treatment with dihydroergotamine, ergotamine, cisapride or colchicine - known g6pd deficiency

- patients with severe form of covid-19 infection defined as the presence of crackles observed during clinical exam, associated with less than 94% oxygen saturation or patients with respiratory insufficiency on oxygen therapy or mechanical ventilation - previous treatment with hydroxychloroquine or azithromycine for covid-19 infection - qtc interval greater than 480 ms - hypersensibility to hydroxychloroquine or azithromycine - retinopathy - tgo or tgp geater than 5 x the normal upper limit - creatinine clearance lower than 30 ml/min - concomitant treatment that may lead to prolongation of the qt space - concomitant treatment with dihydroergotamine, ergotamine, cisapride or colchicine - known g6pd deficiency